|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PPP1R15B |
Gene summary for PPP1R15B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PPP1R15B | Gene ID | 84919 |
| Gene name | protein phosphatase 1 regulatory subunit 15B | |
| Gene Alias | CREP | |
| Cytomap | 1q32.1 | |
| Gene Type | protein-coding | GO ID | GO:0000302 | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84919 | PPP1R15B | LZE4T | Human | Esophagus | ESCC | 1.93e-03 | 1.77e-02 | 0.0811 |
| 84919 | PPP1R15B | LZE7T | Human | Esophagus | ESCC | 1.20e-03 | 3.20e-01 | 0.0667 |
| 84919 | PPP1R15B | LZE8T | Human | Esophagus | ESCC | 3.31e-04 | 2.46e-01 | 0.067 |
| 84919 | PPP1R15B | LZE24T | Human | Esophagus | ESCC | 1.15e-06 | 2.63e-01 | 0.0596 |
| 84919 | PPP1R15B | P1T-E | Human | Esophagus | ESCC | 2.99e-08 | 7.12e-01 | 0.0875 |
| 84919 | PPP1R15B | P2T-E | Human | Esophagus | ESCC | 4.33e-23 | 6.66e-01 | 0.1177 |
| 84919 | PPP1R15B | P4T-E | Human | Esophagus | ESCC | 1.10e-10 | 4.10e-01 | 0.1323 |
| 84919 | PPP1R15B | P5T-E | Human | Esophagus | ESCC | 9.57e-13 | 2.89e-01 | 0.1327 |
| 84919 | PPP1R15B | P8T-E | Human | Esophagus | ESCC | 9.40e-13 | 2.07e-01 | 0.0889 |
| 84919 | PPP1R15B | P9T-E | Human | Esophagus | ESCC | 1.60e-13 | 1.86e-01 | 0.1131 |
| 84919 | PPP1R15B | P10T-E | Human | Esophagus | ESCC | 8.01e-11 | 1.24e-01 | 0.116 |
| 84919 | PPP1R15B | P11T-E | Human | Esophagus | ESCC | 8.29e-12 | 7.57e-01 | 0.1426 |
| 84919 | PPP1R15B | P12T-E | Human | Esophagus | ESCC | 1.64e-07 | 1.98e-03 | 0.1122 |
| 84919 | PPP1R15B | P15T-E | Human | Esophagus | ESCC | 3.38e-16 | 2.74e-01 | 0.1149 |
| 84919 | PPP1R15B | P16T-E | Human | Esophagus | ESCC | 1.61e-15 | 1.05e-01 | 0.1153 |
| 84919 | PPP1R15B | P17T-E | Human | Esophagus | ESCC | 1.92e-02 | 1.03e-02 | 0.1278 |
| 84919 | PPP1R15B | P19T-E | Human | Esophagus | ESCC | 2.89e-03 | 3.54e-01 | 0.1662 |
| 84919 | PPP1R15B | P20T-E | Human | Esophagus | ESCC | 2.86e-03 | 8.13e-02 | 0.1124 |
| 84919 | PPP1R15B | P21T-E | Human | Esophagus | ESCC | 1.88e-14 | 2.85e-01 | 0.1617 |
| 84919 | PPP1R15B | P22T-E | Human | Esophagus | ESCC | 1.55e-14 | 5.53e-02 | 0.1236 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:19001021 | Liver | HCC | negative regulation of endoplasmic reticulum unfolded protein response | 12/7958 | 15/18723 | 3.56e-03 | 1.59e-02 | 12 |
| GO:00364901 | Liver | HCC | regulation of translation in response to endoplasmic reticulum stress | 9/7958 | 11/18723 | 9.51e-03 | 3.60e-02 | 9 |
| GO:190389711 | Liver | HCC | regulation of PERK-mediated unfolded protein response | 9/7958 | 11/18723 | 9.51e-03 | 3.60e-02 | 9 |
| GO:003497620 | Oral cavity | OSCC | response to endoplasmic reticulum stress | 178/7305 | 256/18723 | 2.59e-23 | 6.06e-21 | 178 |
| GO:000697920 | Oral cavity | OSCC | response to oxidative stress | 273/7305 | 446/18723 | 8.35e-22 | 1.65e-19 | 273 |
| GO:000641318 | Oral cavity | OSCC | translational initiation | 96/7305 | 118/18723 | 4.02e-21 | 7.06e-19 | 96 |
| GO:003596620 | Oral cavity | OSCC | response to topologically incorrect protein | 117/7305 | 159/18723 | 6.93e-19 | 8.60e-17 | 117 |
| GO:000641720 | Oral cavity | OSCC | regulation of translation | 274/7305 | 468/18723 | 4.39e-18 | 4.63e-16 | 274 |
| GO:000698620 | Oral cavity | OSCC | response to unfolded protein | 103/7305 | 137/18723 | 6.47e-18 | 6.50e-16 | 103 |
| GO:000030220 | Oral cavity | OSCC | response to reactive oxygen species | 143/7305 | 222/18723 | 1.32e-14 | 7.88e-13 | 143 |
| GO:00064469 | Oral cavity | OSCC | regulation of translational initiation | 64/7305 | 79/18723 | 2.32e-14 | 1.30e-12 | 64 |
| GO:004254219 | Oral cavity | OSCC | response to hydrogen peroxide | 101/7305 | 146/18723 | 1.30e-13 | 6.66e-12 | 101 |
| GO:001056320 | Oral cavity | OSCC | negative regulation of phosphorus metabolic process | 246/7305 | 442/18723 | 6.12e-13 | 2.89e-11 | 246 |
| GO:004593620 | Oral cavity | OSCC | negative regulation of phosphate metabolic process | 245/7305 | 441/18723 | 8.85e-13 | 4.09e-11 | 245 |
| GO:003596720 | Oral cavity | OSCC | cellular response to topologically incorrect protein | 83/7305 | 116/18723 | 1.09e-12 | 4.84e-11 | 83 |
| GO:003462019 | Oral cavity | OSCC | cellular response to unfolded protein | 71/7305 | 96/18723 | 3.45e-12 | 1.35e-10 | 71 |
| GO:004232619 | Oral cavity | OSCC | negative regulation of phosphorylation | 214/7305 | 385/18723 | 2.30e-11 | 7.74e-10 | 214 |
| GO:000647015 | Oral cavity | OSCC | protein dephosphorylation | 162/7305 | 281/18723 | 1.56e-10 | 4.56e-09 | 162 |
| GO:000193319 | Oral cavity | OSCC | negative regulation of protein phosphorylation | 191/7305 | 342/18723 | 1.58e-10 | 4.62e-09 | 191 |
| GO:190589720 | Oral cavity | OSCC | regulation of response to endoplasmic reticulum stress | 60/7305 | 82/18723 | 3.38e-10 | 9.11e-09 | 60 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PPP1R15B | SNV | Missense_Mutation | novel | c.1677N>A | p.Phe559Leu | p.F559L | Q5SWA1 | protein_coding | tolerated(0.07) | probably_damaging(0.999) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | SD | |
| PPP1R15B | SNV | Missense_Mutation | c.171G>C | p.Glu57Asp | p.E57D | Q5SWA1 | protein_coding | deleterious_low_confidence(0.04) | benign(0.073) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| PPP1R15B | SNV | Missense_Mutation | c.1861G>A | p.Asp621Asn | p.D621N | Q5SWA1 | protein_coding | tolerated(0.1) | benign(0.149) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| PPP1R15B | SNV | Missense_Mutation | c.1341N>A | p.Asp447Glu | p.D447E | Q5SWA1 | protein_coding | tolerated(0.2) | possibly_damaging(0.693) | TCGA-B6-A0IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PPP1R15B | SNV | Missense_Mutation | c.742N>C | p.Val248Leu | p.V248L | Q5SWA1 | protein_coding | deleterious(0.03) | benign(0.159) | TCGA-E9-A244-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| PPP1R15B | SNV | Missense_Mutation | novel | c.1531G>C | p.Glu511Gln | p.E511Q | Q5SWA1 | protein_coding | tolerated(0.3) | benign(0.177) | TCGA-LL-A5YM-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unspecific | letrozole | PD |
| PPP1R15B | insertion | Frame_Shift_Ins | novel | c.1228_1229insCC | p.Glu410AlafsTer17 | p.E410Afs*17 | Q5SWA1 | protein_coding | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| PPP1R15B | insertion | Frame_Shift_Ins | novel | c.1226_1227insTGGCCTTCCAAAGTGCTGGGATTACAGGCGTG | p.Glu410GlyfsTer27 | p.E410Gfs*27 | Q5SWA1 | protein_coding | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| PPP1R15B | insertion | Frame_Shift_Ins | novel | c.1024_1025insGTCCATTGTGGCCATTTCTGAGTGTC | p.Asn342SerfsTer33 | p.N342Sfs*33 | Q5SWA1 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| PPP1R15B | insertion | Frame_Shift_Ins | novel | c.181_182insTTCTTAGTTGGGAATATTCTGAAAGAATTGGTAGCATAAAGGG | p.Ser61IlefsTer95 | p.S61Ifs*95 | Q5SWA1 | protein_coding | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |